<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969172</url>
  </required_header>
  <id_info>
    <org_study_id>0206-21-TLV</org_study_id>
    <nct_id>NCT04969172</nct_id>
  </id_info>
  <brief_title>A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Sprecher, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OBCTCD24 Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and&#xD;
      efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study&#xD;
      population will include patients with moderate or severe COVID-19 infection and laboratory&#xD;
      markers predictive of the cytokine storm from the Corona department of each site, who have&#xD;
      provided an informed consent.&#xD;
&#xD;
      155 patients will be randomized in a 2:1 ratio to receive either 1010 exosome particles (103&#xD;
      patients) or placebo (52 patients).The exosomes will be diluted in 4ml normal saline for&#xD;
      inhalation, administered once daily (QD) for 5 days.&#xD;
&#xD;
      Placebo (saline) will be prepared for inhalation and administered in the same manner as the&#xD;
      exosomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The exosomes will be diluted in 4ml normal saline for inhalation, administered once daily&#xD;
      (QD) for 5 days.&#xD;
&#xD;
      Placebo (saline) will be prepared for inhalation and administered in the same manner as the&#xD;
      exosomes.&#xD;
&#xD;
      Study treatments will be given as add-on to standard of care. Following the 5 days of&#xD;
      treatment, patients will remain in follow-up for 23 additional days. Patients who will be&#xD;
      discharged before the end of the 5-day treatment period will continue to receive treatment at&#xD;
      home. Treatment administration and the study assessments will be carried out by the research&#xD;
      personnel at the home of the patient, implementing the required protective measures.&#xD;
&#xD;
      On Day 28, when the isolation period is completed, these patients will arrive at the study&#xD;
      site for the follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 11, 2021</start_date>
  <completion_date type="Anticipated">July 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study population will include patients with moderate or severe COVID-19 infection and laboratory markers predictive of the cytokine storm from the Corona department of each site, who have provided an informed consent.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>155 patients will be randomized in a 2:1 ratio to receive either 1010 exosome particles -103 patients, or placebo- 52 patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of EXO-CD24 in the treatment of patients with moderate or severe COVID-19 disease</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the efficacy of EXO-CD24 in the clinical improvement of COVID-19 disease</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate respiratory failure (defined as the need for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow oxygen devices) rate.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the death rate.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate time to improvement and recovery (COVID-19 clinical severity score of 3 or lower).</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate time from hospitalization to hospital discharge.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the COVID-19-related symptoms using patient-reported outcome measure (PRO) score.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of EXO-CD24 on the respiratory rate.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of EXO-CD24 on the change in blood oxygen saturation (SpO2).</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of EXO-CD24 on the proportion of patients requiring ventilation.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of EXO-CD24 on the level of inflammatory markers (eg, CRP, ferritin, fibrinogen, di-dimers, IL-6, LDH, lymphocytes count.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>COVID-19 Disease</condition>
  <arm_group>
    <arm_group_label>1010 Exosome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>103 patients will receive either 1010 exosome particles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>52 patients will receive placebo- saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exosomes overexpressing CD24</intervention_name>
    <description>The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.</description>
    <arm_group_label>1010 Exosome</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A COVID-19 diagnosis confirmed with a SARS-coV-2 viral infection positive polymerase&#xD;
             chain reaction (PCR) test&#xD;
&#xD;
          2. Age 18-80 years&#xD;
&#xD;
          3. Severity of disease according to the following criteria (at least one clinical&#xD;
             parameter and one laboratory parameter are required):&#xD;
&#xD;
             a. Clinical and Imaging-based evaluation i. Respiratory rate &gt; 23/min and &lt; 30/min ii.&#xD;
             SpO2 at room air ≤94% and ≥90% iii. Bilateral pulmonary infiltrates &gt;50% within 24-48&#xD;
             hours or a severe deterioration compared to imaging at admission b. Evidence of an&#xD;
             exacerbated inflammatory process i. LDH score&gt; 450 U/L ii. CRP &gt;50 mg/L iii. Ferritin&#xD;
             &gt;1650 ng/ml iv. Lymphocytes &gt;800 cells/mm3 v. D-dimers &gt;1 mcg/ml&#xD;
&#xD;
          4. Willing and able to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age&lt;18 years or &gt;80 years&#xD;
&#xD;
          2. Any concomitant illness that, based on the judgment of the Investigator is terminal&#xD;
&#xD;
          3. Ventilated patient&#xD;
&#xD;
          4. Pregnancy (positive urine pregnancy test [women of childbearing potential only]) or&#xD;
             breastfeeding&#xD;
&#xD;
          5. Patients with Immunodeficiency (eg, CLL, HIV, rituximab therapy)&#xD;
&#xD;
          6. Unwilling or unable to provide informed consent&#xD;
&#xD;
          7. Participation in any other Interventional study in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Eli Sprecher, MD</investigator_full_name>
    <investigator_title>Dr. Guy Choshen</investigator_title>
  </responsible_party>
  <keyword>AE- Adverse event</keyword>
  <keyword>BUN - Blood urea nitrogen</keyword>
  <keyword>CI- Confidence Interval</keyword>
  <keyword>CMP - Clinical monitoring plan</keyword>
  <keyword>CONSORT- Consolidated Standards of Reporting Trials</keyword>
  <keyword>CRF - Case Report Form</keyword>
  <keyword>DAMP- Damage-associated molecular patterns</keyword>
  <keyword>DMEM- Dulbecco's Modified Eagle's Medium</keyword>
  <keyword>GCP - Good Clinical Practice</keyword>
  <keyword>GMP- Good Manufacturing Practice</keyword>
  <keyword>GVHD- Graft-versus-host disease</keyword>
  <keyword>HCT - Hematopoietic stem cell transplantation</keyword>
  <keyword>ICH- International Conference on Harmonization</keyword>
  <keyword>IDSA- Infectious Diseases Society of America</keyword>
  <keyword>IRB- Institutional Review Board</keyword>
  <keyword>ITT- Intend-to-Treat analysis set</keyword>
  <keyword>mITT- Modified Intent-to-Treat analysis set</keyword>
  <keyword>NLR - Neutrophil-to-lymphocyte ratio</keyword>
  <keyword>PCR - Polymerase chain reaction</keyword>
  <keyword>PI- Principal Investigator</keyword>
  <keyword>PP- Per-Protocol analysis set</keyword>
  <keyword>SA- Safety analysis set</keyword>
  <keyword>SAE- Serious adverse event</keyword>
  <keyword>SoA- Schedule of Activities</keyword>
  <keyword>TLR- Toll-like receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Clinical Deterioration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

